This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetesGwilt M, Ryder REJ, Holman RRBritish Journal of Diabetes 2016;16:88-92. Published:Jun-2016. doi:10.15277/bjd.2016.082